[go: up one dir, main page]

MX2012000498A - Uso de bencidamina en el tratamiento de enfermedades dependientes de p40. - Google Patents

Uso de bencidamina en el tratamiento de enfermedades dependientes de p40.

Info

Publication number
MX2012000498A
MX2012000498A MX2012000498A MX2012000498A MX2012000498A MX 2012000498 A MX2012000498 A MX 2012000498A MX 2012000498 A MX2012000498 A MX 2012000498A MX 2012000498 A MX2012000498 A MX 2012000498A MX 2012000498 A MX2012000498 A MX 2012000498A
Authority
MX
Mexico
Prior art keywords
benzydamine
treatment
dependent diseases
overexpression
psoriasis
Prior art date
Application number
MX2012000498A
Other languages
English (en)
Inventor
Angelo Guglielmotti
Giorgina Mangano
Giuseppe Biondi
Original Assignee
Acraf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acraf filed Critical Acraf
Publication of MX2012000498A publication Critical patent/MX2012000498A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Uso de bencidamina en el tratamiento de enfermedades inflamatorias, en particular enfermedad de Crohn, artritis reumatoide, artritis psoriasica y psoriasis causada por una expresión o sobreexpresión de la subunidad de citoquina p40.
MX2012000498A 2009-07-08 2010-06-23 Uso de bencidamina en el tratamiento de enfermedades dependientes de p40. MX2012000498A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09425270 2009-07-08
PCT/EP2010/058881 WO2011003737A1 (en) 2009-07-08 2010-06-23 USE OF BENZYDAMINE IN THE TREATMENT OF p40-DEPENDENT DISEASES

Publications (1)

Publication Number Publication Date
MX2012000498A true MX2012000498A (es) 2012-04-30

Family

ID=41279454

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012000498A MX2012000498A (es) 2009-07-08 2010-06-23 Uso de bencidamina en el tratamiento de enfermedades dependientes de p40.

Country Status (25)

Country Link
US (1) US20120302618A1 (es)
EP (1) EP2451452B1 (es)
JP (1) JP5753843B2 (es)
KR (1) KR101723996B1 (es)
CN (1) CN102470125B (es)
AR (1) AR077451A1 (es)
AU (1) AU2010270425B2 (es)
BR (1) BR112012000410B8 (es)
CA (1) CA2760176C (es)
CY (1) CY1116914T1 (es)
DK (1) DK2451452T3 (es)
EA (1) EA022862B1 (es)
ES (1) ES2554332T3 (es)
GE (1) GEP20146156B (es)
HR (1) HRP20151393T8 (es)
HU (1) HUE028220T2 (es)
IL (1) IL216717A (es)
MX (1) MX2012000498A (es)
PL (1) PL2451452T3 (es)
PT (1) PT2451452E (es)
SG (2) SG176686A1 (es)
SI (1) SI2451452T1 (es)
SM (1) SMT201500277B (es)
UA (1) UA105666C2 (es)
WO (1) WO2011003737A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107873024A (zh) * 2015-02-09 2018-04-03 塞尔利克斯生物私人有限公司 用于治疗粘膜炎的组合物和方法
WO2017044752A1 (en) * 2015-09-10 2017-03-16 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Anti-fibrotic effect of cd70
CN109562058A (zh) * 2016-07-08 2019-04-02 方济各安吉利克化学联合股份有限公司 包含苄达明的药物组合物

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1054833A (es) 1963-08-09
IT1184123B (it) 1985-01-22 1987-10-22 Acraf Impiego della benzidamina nel trattamento delle infezioni da trichomonas vaginalis e gardnerella vaginalis
IT1276040B1 (it) * 1993-07-27 1997-10-24 Angelini Francesco Ist Ricerca Uso della benzidamina nel trattamento di stati patologici causati dal tnf
IT1274026B (it) 1994-03-01 1997-07-14 Acraf Composizione antitosse
IT1274655B (it) * 1995-02-28 1997-07-18 Smithkline Beecham Farma Composizioni farmaceutiche contenenti un agente antiinfiammatorio e un agente antimicrobico
EP1848403B8 (en) * 2005-01-14 2010-05-19 Camurus Ab Topical bioadhesive formulations
ES2343641T3 (es) * 2005-01-14 2010-08-05 Camurus Ab Formulaciones bioadhesivas topicas.
GB0604824D0 (en) * 2006-03-09 2006-04-19 Arakis Ltd The treatment of inflammatory disorders

Also Published As

Publication number Publication date
CA2760176A1 (en) 2011-01-13
EP2451452A1 (en) 2012-05-16
IL216717A (en) 2017-06-29
US20120302618A1 (en) 2012-11-29
CN102470125B (zh) 2015-08-19
CY1116914T1 (el) 2017-04-05
CN102470125A (zh) 2012-05-23
DK2451452T3 (en) 2015-11-23
PT2451452E (pt) 2016-01-14
BR112012000410B1 (pt) 2019-12-31
AU2010270425A1 (en) 2011-12-22
EA201270143A1 (ru) 2012-06-29
SMT201500277B (it) 2016-01-08
AU2010270425B2 (en) 2016-07-28
SG176686A1 (en) 2012-01-30
PL2451452T3 (pl) 2016-03-31
HK1165280A1 (zh) 2012-11-23
SI2451452T1 (sl) 2015-12-31
HUE028220T2 (en) 2016-12-28
SG10201403088XA (en) 2014-10-30
JP5753843B2 (ja) 2015-07-22
EP2451452B1 (en) 2015-10-07
EA022862B1 (ru) 2016-03-31
HRP20151393T1 (hr) 2016-01-15
IL216717A0 (en) 2012-02-29
GEP20146156B (en) 2014-09-10
ES2554332T3 (es) 2015-12-18
AR077451A1 (es) 2011-08-31
KR20120052201A (ko) 2012-05-23
CA2760176C (en) 2017-01-03
HRP20151393T8 (hr) 2016-07-01
JP2012532173A (ja) 2012-12-13
BR112012000410B8 (pt) 2020-12-08
UA105666C2 (uk) 2014-06-10
BR112012000410A2 (pt) 2016-04-05
KR101723996B1 (ko) 2017-04-06
WO2011003737A1 (en) 2011-01-13

Similar Documents

Publication Publication Date Title
IL215579A0 (en) Novel 1-benzyl-3-hydroxymethylindazole derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, cx3cr1 and p40
UA108198C2 (uk) Заміщені 2-ацетамідо-5-арил-1,2,4-триазолони та їх застосування
PT2334677E (pt) Compostos de triazolopiridina como inibidores das quinases pim
MX2017001671A (es) Formulaciones novedosas de un inhibidor de la tirosina cinasa de bruton.
MX2009009079A (es) Anticuerpos anti-il-23p19 de ingenieria.
MX2009009080A (es) Anticuerpos anti-interleucina-23p19 manipulados por ingenieria genetica.
MX2009007406A (es) Formulaciones de anticuerpo anti-il-13 y usos de las mismas.
TW200637522A (en) Skin treatment articles and methods
TW200732347A (en) VEGF analogs and methods of use
PH12014501815A1 (en) Purinone compounds as kinase inhibitors
PL2262778T3 (pl) Pochodne 1-benzylo-3-hydroksymetyloindazolu i ich zastosowanie w leczeniu chorób opartych na ekspresji MCP-1, CXCR1 i p40
MX2010000098A (es) Derivados de guanina policiclicos y sus metodos de uso.
MX2009009283A (es) Anticuerpos anti-interleuquina -23r de ingenieria.
SG10201803862UA (en) Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
IN2012DN02471A (es)
MX2009009190A (es) Compuestos heterociclicos, composiciones que los comprenden y metodos que los emplean.
EA201171043A1 (ru) Композиции и способы длительной терапии с применением аминопиридинов
SG179135A1 (en) Methods for treating psoriasis
UA105384C2 (ru) Лечение нарушений, связанных с инсулинорезистентностью
UY33219A (es) Cetoenoles cíclicos para terapias
WO2018033941A3 (en) Pharmaceutical compositions of ibrutinib
MX2013002121A (es) Quinolina-3-carboxamidas sustituidas como moduladores de kcnq2/3.
TW200716091A (en) New therapeutic combinations for the treatment or prevention of psychotic disorders
UA105666C2 (uk) ЗАСТОСУВАННЯ БЕНЗИДАМІНУ ПРИ ЛІКУВАННІ p40-ЗАЛЕЖНИХ ЗАХВОРЮВАНЬ
IN2012DN00928A (es)